Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Stanford Medicine Outpatient Center-Medical Dermatology Clinic
mi
from 02139
Redwood City, CA
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Stanford Medicine Outpatient Center-Medical Dermatology Clinic
mi
from 02139
Redwood City, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DermResearchCenter of New York, Inc
145
mi
from 02139
Stony Brook, NY
A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DermResearchCenter of New York, Inc
145
mi
from 02139
Stony Brook, NY
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Total Skin and Beauty Dermatology Center
1048
mi
from 02139
Birmingham, AL
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Total Skin and Beauty Dermatology Center
1048
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Radiant Tucson
2274
mi
from 02139
Tucson, AZ
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Radiant Tucson
2274
mi
from 02139
Tucson, AZ
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Johnson Dermatology
1338
mi
from 02139
Fort Smith, AR
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Johnson Dermatology
1338
mi
from 02139
Fort Smith, AR
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
First OC Dermatology
2584
mi
from 02139
Fountain Valley, CA
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
First OC Dermatology
2584
mi
from 02139
Fountain Valley, CA
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
University Clinical Trials, Inc.
2576
mi
from 02139
San Diego, CA
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
University Clinical Trials, Inc.
2576
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Horizons Clinical Research Center, LLC
1760
mi
from 02139
Denver, CO
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Horizons Clinical Research Center, LLC
1760
mi
from 02139
Denver, CO
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Belleair Research Center
1196
mi
from 02139
Pinellas Park, FL
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Belleair Research Center
1196
mi
from 02139
Pinellas Park, FL
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Dermatology Group
802
mi
from 02139
Indianapolis, IN
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Dermatology Group
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
The Indiana Clinical Trials Center, PC
816
mi
from 02139
Plainfield, IN
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
The Indiana Clinical Trials Center, PC
816
mi
from 02139
Plainfield, IN
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
South Bend Clinic
777
mi
from 02139
South Bend, IN
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
South Bend Clinic
777
mi
from 02139
South Bend, IN
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Kansas City Dermatology, PA
1256
mi
from 02139
Overland Park, KA
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Kansas City Dermatology, PA
1256
mi
from 02139
Overland Park, KA
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Somerset Skin Centre
615
mi
from 02139
Troy, MI
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Somerset Skin Centre
615
mi
from 02139
Troy, MI
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Oregon Medical Research Center, PC
2536
mi
from 02139
Portland, OR
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Oregon Medical Research Center, PC
2536
mi
from 02139
Portland, OR
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arlington Research Center
1562
mi
from 02139
Arlington, TX
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arlington Research Center
1562
mi
from 02139
Arlington, TX
Click here to add this to my saved trials
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Progressive Clinical Research
1763
mi
from 02139
San Antonio, TX
AGN-242428 in the Treatment of Plaque Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Progressive Clinical Research
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1052
mi
from 02139
Birmingham, AL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1052
mi
from 02139
Birmingham, AL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Center for Dermatology Clinical Research
2674
mi
from 02139
Fremont, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Center for Dermatology Clinical Research
2674
mi
from 02139
Fremont, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Science Institute
2600
mi
from 02139
Santa Monica, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Science Institute
2600
mi
from 02139
Santa Monica, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Danbury Clinical Research, LLC
138
mi
from 02139
Danbury, CT
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Danbury Clinical Research, LLC
138
mi
from 02139
Danbury, CT
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
International Dermatology Research, Inc.
1260
mi
from 02139
Miami, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
International Dermatology Research, Inc.
1260
mi
from 02139
Miami, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Medical Dermatology Specialists
927
mi
from 02139
Atlanta, GA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Medical Dermatology Specialists
927
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Northwestern University
845
mi
from 02139
Chicago, IL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University
845
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
The Indiana Clinical Trials Center, PC
816
mi
from 02139
Plainfield, IN
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
The Indiana Clinical Trials Center, PC
816
mi
from 02139
Plainfield, IN
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Wake Research, LLC
607
mi
from 02139
Raleigh, NC
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Wake Research, LLC
607
mi
from 02139
Raleigh, NC
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatologists of Greater Columbus
640
mi
from 02139
Bexley, OH
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatologists of Greater Columbus
640
mi
from 02139
Bexley, OH
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
National Allergy and Asthma Research, LLC
815
mi
from 02139
North Charleston, SC
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
National Allergy and Asthma Research, LLC
815
mi
from 02139
North Charleston, SC
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
University Hospital Antwerp
3463
mi
from 02139
Antwerp,
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
University Hospital Antwerp
3463
mi
from 02139
Antwerp,
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
California Dermatology and Clinical Research Institute
2572
mi
from 02139
Encinitas, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
California Dermatology and Clinical Research Institute
2572
mi
from 02139
Encinitas, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
First OC Dermatology
2584
mi
from 02139
Fountain Valley, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
First OC Dermatology
2584
mi
from 02139
Fountain Valley, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Respiratory Medicine Research
mi
from 02139
Ypsilanti, MI
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Respiratory Medicine Research
mi
from 02139
Ypsilanti, MI
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Oregon Dermatology & Research
mi
from 02139
Portland, OR
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Oregon Dermatology & Research
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Dermatology Research Associates
2599
mi
from 02139
Los Angeles, CA
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Dermatology Research Associates
2599
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
L & C Professional Medical Research
mi
from 02139
Miami, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
L & C Professional Medical Research
mi
from 02139
Miami, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Lenus Research & Medical Group
1192
mi
from 02139
Sweetwater, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Lenus Research & Medical Group
1192
mi
from 02139
Sweetwater, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Olympian Clinical Research
1184
mi
from 02139
Tampa, FL
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Olympian Clinical Research
1184
mi
from 02139
Tampa, FL
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Study Center
mi
from 02139
Bangor, ME
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Study Center
mi
from 02139
Bangor, ME
Click here to add this to my saved trials
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
Mount Sinai West Dermatoogy
mi
from 02139
New York, NY
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Mount Sinai West Dermatoogy
mi
from 02139
New York, NY
Click here to add this to my saved trials
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects
Status: Enrolling
Updated:  12/31/1969
Local Institution
2088
mi
from 02139
Salt Lake City, UT
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects
Status: Enrolling
Updated: 12/31/1969
Local Institution
2088
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 009
1234
mi
from 02139
Mobile, AL
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 009
1234
mi
from 02139
Mobile, AL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 007
2588
mi
from 02139
Los Angeles, CA
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 007
2588
mi
from 02139
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 011
607
mi
from 02139
Warren, MI
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 011
607
mi
from 02139
Warren, MI
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 005
267
mi
from 02139
Berlin, NJ
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 005
267
mi
from 02139
Berlin, NJ
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 002
1490
mi
from 02139
Oklahoma City, OK
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 002
1490
mi
from 02139
Oklahoma City, OK
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 010
1601
mi
from 02139
Houston, TX
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 010
1601
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Sienna 001
1763
mi
from 02139
San Antonio, TX
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Sienna 001
1763
mi
from 02139
San Antonio, TX
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1260
mi
from 02139
Coral Gables, FL
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1260
mi
from 02139
Coral Gables, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
802
mi
from 02139
Indianapolis, IN
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2596
mi
from 02139
Sherman Oaks, CA
Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2596
mi
from 02139
Sherman Oaks, CA
Click here to add this to my saved trials